全文获取类型
收费全文 | 73681篇 |
免费 | 6182篇 |
国内免费 | 3354篇 |
专业分类
耳鼻咽喉 | 222篇 |
儿科学 | 1382篇 |
妇产科学 | 880篇 |
基础医学 | 13186篇 |
口腔科学 | 779篇 |
临床医学 | 5668篇 |
内科学 | 17046篇 |
皮肤病学 | 1104篇 |
神经病学 | 2839篇 |
特种医学 | 1916篇 |
外国民族医学 | 9篇 |
外科学 | 4028篇 |
综合类 | 10849篇 |
现状与发展 | 19篇 |
预防医学 | 6080篇 |
眼科学 | 506篇 |
药学 | 9040篇 |
20篇 | |
中国医学 | 3553篇 |
肿瘤学 | 4091篇 |
出版年
2023年 | 789篇 |
2022年 | 1427篇 |
2021年 | 2372篇 |
2020年 | 2196篇 |
2019年 | 2481篇 |
2018年 | 2337篇 |
2017年 | 2290篇 |
2016年 | 2672篇 |
2015年 | 2938篇 |
2014年 | 4831篇 |
2013年 | 5098篇 |
2012年 | 4941篇 |
2011年 | 5245篇 |
2010年 | 4252篇 |
2009年 | 4116篇 |
2008年 | 4064篇 |
2007年 | 3903篇 |
2006年 | 3551篇 |
2005年 | 3054篇 |
2004年 | 2512篇 |
2003年 | 2192篇 |
2002年 | 1760篇 |
2001年 | 1562篇 |
2000年 | 1206篇 |
1999年 | 1060篇 |
1998年 | 965篇 |
1997年 | 801篇 |
1996年 | 682篇 |
1995年 | 696篇 |
1994年 | 598篇 |
1993年 | 497篇 |
1992年 | 469篇 |
1991年 | 383篇 |
1990年 | 341篇 |
1989年 | 306篇 |
1988年 | 255篇 |
1987年 | 221篇 |
1986年 | 185篇 |
1985年 | 492篇 |
1984年 | 507篇 |
1983年 | 425篇 |
1982年 | 423篇 |
1981年 | 363篇 |
1980年 | 327篇 |
1979年 | 302篇 |
1978年 | 225篇 |
1977年 | 179篇 |
1976年 | 196篇 |
1975年 | 159篇 |
1974年 | 136篇 |
排序方式: 共有10000条查询结果,搜索用时 31 毫秒
41.
Auda A. Eltahla Fabio Luciani Peter A. White Andrew R. Lloyd Rowena A. Bull 《Viruses》2015,7(10):5206-5224
The hepatitis C virus (HCV) is a pandemic human pathogen posing a substantial health and economic burden in both developing and developed countries. Controlling the spread of HCV through behavioural prevention strategies has met with limited success and vaccine development remains slow. The development of antiviral therapeutic agents has also been challenging, primarily due to the lack of efficient cell culture and animal models for all HCV genotypes, as well as the large genetic diversity between HCV strains. On the other hand, the use of interferon-α-based treatments in combination with the guanosine analogue, ribavirin, achieved limited success, and widespread use of these therapies has been hampered by prevalent side effects. For more than a decade, the HCV RNA-dependent RNA polymerase (RdRp) has been targeted for antiviral development. Direct acting antivirals (DAA) have been identified which bind to one of at least six RdRp inhibitor-binding sites, and are now becoming a mainstay of highly effective and well tolerated antiviral treatment for HCV infection. Here we review the different classes of RdRp inhibitors and their mode of action against HCV. Furthermore, the mechanism of antiviral resistance to each class is described, including naturally occurring resistance-associated variants (RAVs) in different viral strains and genotypes. Finally, we review the impact of these RAVs on treatment outcomes with the newly developed regimens. 相似文献
42.
《Vaccine》2020,38(10):2315-2325
In the preparation of glycoconjugate vaccines in clinical practice, two highly immunogenic carrier proteins, CRM197 and tetanus toxoid (TT), are predominantly conjugated with the capsular polysaccharides (CPSs) of bacterial pathogens. In addition, TT has long been used as an effective vaccine to prevent tetanus. While these carrier proteins play an important role in immunogenicity and vaccine design alike, their defined human major histocompatibility complex class II (MHCII) T cell epitopes are inadequately characterized. In this current work, we use mass spectrometry to identify the peptides from these carrier proteins that are naturally processed and presented by human B cells via MHCII pathway. The MHCII-presented peptides are screened for their T cell stimulation using primary CD4+ T cells from four healthy adult donors. These combined methods reveal a subset of eleven CD4+ T cell epitopes that proliferate and stimulate human T cells with diverse MHCII allelic repertoire. Six of these peptides stand out as potential immunodominant epitopes by responding in three or more donors. Additionally, we provide evidence of these natural epitopes eliciting more significant T cell responses in donors than previously published TT peptides selected from T cell epitope screening. This study serves toward understanding carrier protein immune responses and thus enables the use of these peptides in developing novel knowledge-based vaccines to combat persisting problems in glycoconjugate vaccine design. 相似文献
43.
44.
目的:观察地黄饮子加减方对血管性痴呆模型大鼠学习记忆能力及海马CA1区神经元的影响。方法:将84只SD雄性大鼠,按随机原则选出12只大鼠作为假手术组,其余72只大鼠采用两血管阻断法制备血管性痴呆模型,筛选60只模型大鼠,每组12只,随机分为模型组,尼莫地平组(0. 011 g·kg~(-1)),地黄饮子加减方高、中、低(4. 54,2. 27,1. 14 g·kg~(-1))剂量组。连续灌胃30 d后,Morris水迷宫检测大鼠学习记忆能力,苏木素-伊红(HE)观察海马CA1区神经元形态结构改变,透射电镜观察海马CA1区神经元超微结构变化,原位细胞凋亡检测法(TUNEL)检测海马CA1区细胞凋亡水平,免疫组化(IHC)检测海马CA1区组织磷脂酰肌醇3-激酶(PI3K),蛋白激酶B(Akt),半胱氨酸蛋白酶-3(Caspase-3)表达水平。结果:与假手术组比较,模型组大鼠逃避潜伏期显著延长,穿越原平台次数显著减少(P 0. 01),海马CA1区神经元形态均有不同程度地损伤,凋亡率显著增加(P 0. 01),PI3K,Akt的积分吸光度和平均积分吸光度明显降低(P 0. 01),Caspase-3的积分吸光度和平均积分吸光度显著增高(P 0. 01);与模型组比较,各给药组大鼠逃避潜伏期缩短(P 0. 05,P 0. 01),穿越原平台次数增加(P 0. 05,P 0. 01),PI3K,Akt的积分吸光度和平均积分吸光度值显著增高(P 0. 01),Caspase-3的积分光密度和平均积分吸光度不同程度降低(P 0. 05,P 0. 01)。结论:地黄饮子加减方可改善血管性痴呆模型大鼠学习记忆能力和海马CA1区神经元损伤,潜在机制可能与PI3K/Akt信号转导途径的激活,抑制大鼠海马CA1区神经细胞的凋亡有关。 相似文献
45.
《Molecular immunology》2015,63(2):296-304
Regulatory B cells (Bregs) are defined by their ability to restrain inflammatory responses both in vivo and in vitro. Interleukin 10 (IL-10) production by Bregs is thought to be central to their ability to regulate inflammation, largely due to IL-10s’ ability to suppress pro-inflammatory cytokine production by effector lymphocytes and to maintain the differentiation of regulatory T cells (Tregs). However, with an increase in available published data, it has become evident that Bregs utilize a number of suppressive mechanisms in order to alter the activation of a variety of different lymphocytes. Here, we summarize the multiplicity of cellular targets of Breg-mediated suppression and describe the mechanisms employed by Bregs to suppress chronic inflammatory responses. 相似文献
46.
《中医科学杂志(英文)》2020,7(3):255-264
ObjectiveIn this study, we used HepG2 human hepatocellular carcinoma cells to study the effects of Compound Xishu Granule (CXG) on cell proliferation, apoptosis, and the cell cycle in vitro. We also used a xenograft tumor model to study the anti-tumor effects of CXG and related mechanisms in vivo.MethodsThe effect of CXG on cell viability was measured using Cell Counting Kit-8 and a colony formation assay. The effect of CXG on apoptosis and the cell cycle was analyzed using flow cytometry. The in vivo anti-tumor effect of CXG was assessed by measuring the volume change in xenograft tumors after drug administration. The CXG anti-tumor mechanism was studied using western blotting assay to detect cell cycle and apoptotic associated proteins.ResultsCXG suppressed HepG2 cell proliferation in a time- and dose-dependent manner in vitro. Colony formation experiments showed that CXG administration for 24 h significantly reduced HepG2 cell formations (P < .01). Flow cytometric analysis showed that CXG treatment for 48 h promoted apoptosis and blocked HepG2 cells in the G2/M phase. Western blotting results showed that Bax was significantly up-regulated and Bcl-2 was down-regulated in graft tumor tissues and HepG2 cells after CXG administration, which increased the Bax/Bcl-2 ratio. PLK1, CDC25C, CDK1, and Cyclin B1 expression were up-regulated. CXG had a good inhibitory effect on graft tumor growth in vivo.ConclusionCXG has good anti-tumor effects in vitro and in vivo. In vitro, CXG promoted HepG2 cell apoptosis and induced G2/M phase arrest. In vivo, CXG significantly inhibited graft tumor growth. The CXG mechanism in treating hepatocellular carcinoma may be that CXG can induce abnormal apoptotic and cell cycle associated protein expression, leading to mitotic catastrophe and apoptosis. 相似文献
47.
48.
49.
50.
《Radiography》2020,26(4):e195-e200
IntroductionAdverse events in radiology are quite rare, but they do occur. Radiation safety regulations and the law obligate organizations to report certain adverse events, harm and near misses, especially events related to patients' health and safety. The aim of this study was to describe and analyse incidents related to radiation safety issues reported in Finland.MethodsThe data were collected from incident reports documented by radiology personnel concerning notifications of abnormal events in medical imaging made to the Radiation and Nuclear Safety Authority between 2010 and 2017. During these eight years, 312 reports were submitted. Only events reported from radiology departments were included; nuclear medicine, radiotherapy and animal radiology cases were excluded. The final number of reports was 293 (94%).ResultsThe majority of the 293 approved reports were related to computed tomography (CT, 68.3%) and to X-ray examinations (27.6%). Altogether 82.9% of those irradiated were adults, most of whom were exposed to unnecessary radiation through CT (86.5%), 5.5% were children, and 4.4% pregnant women. The most common effective dose of unnecessary radiation was 1 mSv or less (89.7% of all examinations). The highest effective doses were reported in CT (from under 1 mSv–20 mSv and above). The reasons for the adverse events were incorrect identification (32%), incorrect procedure, site or side (30%); and human errors or errors of knowledge (20%).ConclusionAdverse events occurred especially in CT examinations. It is important to collect and analyse incident data, assess the harmful events, learn from them and aim to reduce adverse events.Implications for practiceThis study emphasizes the need for radiological personnel to obtain evidence-based information on adverse events and focus on training to improve patient safety. 相似文献